Cloud-Clone pushes into flow cytometry antibodies

Cloud-Clone says it has built an in-house flow cytometry antibody platform aimed at reducing cost, lead times and supply-chain risk for researchers and biopharma customers. The company is leaning on its own clone library, conjugation workflows and quality controls to position itself as an alternative to overseas suppliers.

Why it matters: - Flow cytometry antibodies are core reagents for research, precision medicine, cell therapy development and hematology screening. - Cloud-Clone is targeting a market long dominated by overseas suppliers, where buyers face high costs, long lead times, fragile supply chains and limited technical support. - The company says its portfolio is designed to give labs and biopharmaceutical customers more independent and resilient reagent options.

What happened: - Cloud-Clone unveiled an end-to-end, in-house flow cytometry antibody platform in Houston on September 21, 2026. - The company says nearly 20 years of immunology reagent development underpins the effort. - Cloud-Clone says the platform addresses technical gaps in flow cytometry antibodies and breaks long-standing supplier monopolies.

The details: - Cloud-Clone says its internal resource library includes more than 18,000 protein target antigens and more than 45,000 hybridoma cell lines. - Antigen design, recombinant-protein expression, animal immunization and clone screening are completed internally. - The company says its R&D team selects high-affinity monoclonal cell lines and optimizes them for flow-cytometry targets to reduce non-specific binding. - Cloud-Clone says the antibodies deliver strong specificity, low background noise, well-separated cell populations and sharp histogram peaks. - The company says its fluorophore conjugation workflows cover FITC, PE, APC, PerCP-Cy5.5 and PE-Cy7. - Cloud-Clone says it improves labeling uniformity and stability by optimizing conjugation ratios and reaction parameters. - The company says standard manufacturing and large-scale production lines reduce batch-to-batch variation. - Cloud-Clone says its antibodies maintain consistent activity, specificity and fluorescence intensity across batches. - The company says its fluorophore spectral matching helps reduce channel overlap and spillover in multicolor assays. - Cloud-Clone says it follows ISO13485 and ISO9001 quality-management requirements from raw-material intake through finished-product release. - Each batch undergoes sensitivity, specificity and stability testing, along with instrument validation, the company says. - Cloud-Clone says its products are suited for clinical pathological testing, cell-therapy R&D and custom development for pharmaceutical partners. - The company says its broader product lineup includes proteins, antibodies, ELISA kits, primary cells, multiplex cytokine assay kits and CRO services. - Cloud-Clone provides more information at the company's website. - The company also lists social channels on LinkedIn, Instagram, TikTok and X.

Between the lines: - The announcement is as much about supply-chain control as product performance. - Cloud-Clone is framing in-house clone development and standardized manufacturing as the main defenses against specificity problems, lot variability and spillover in multicolor flow cytometry. - The company is also signaling a move toward higher-compliance, higher-end workflows where clinical and biopharma customers care about traceability and validation.

What's next: - Cloud-Clone says it will keep refining manufacturing workflows, expanding its target portfolio and upgrading compliant product lines. - The company says it will continue investing in technical innovation to widen its validated antibody catalog. - Cloud-Clone is pitching the effort as part of a broader push for safer, more resilient global biological-reagent supply chains.

The bottom line: - Cloud-Clone is betting that in-house antibody development, tighter quality control and broader fluorophore coverage can win buyers looking for alternatives to established foreign suppliers.